ArrowMark Colorado Holdings LLC Purchases 842,509 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

ArrowMark Colorado Holdings LLC lifted its stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) by 30.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,647,291 shares of the company's stock after purchasing an additional 842,509 shares during the quarter. ArrowMark Colorado Holdings LLC owned 7.05% of PMV Pharmaceuticals worth $5,434,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in PMVP. PFM Health Sciences LP grew its position in PMV Pharmaceuticals by 57.7% during the 3rd quarter. PFM Health Sciences LP now owns 2,011,040 shares of the company's stock worth $2,996,000 after acquiring an additional 735,578 shares during the last quarter. Sio Capital Management LLC grew its holdings in shares of PMV Pharmaceuticals by 18.7% during the third quarter. Sio Capital Management LLC now owns 3,214,239 shares of the company's stock worth $4,789,000 after purchasing an additional 505,831 shares during the last quarter. BML Capital Management LLC increased its stake in shares of PMV Pharmaceuticals by 29.0% in the third quarter. BML Capital Management LLC now owns 1,688,772 shares of the company's stock valued at $2,516,000 after buying an additional 379,375 shares during the period. Assenagon Asset Management S.A. raised its holdings in PMV Pharmaceuticals by 36.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,837 shares of the company's stock valued at $527,000 after buying an additional 93,809 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in PMV Pharmaceuticals by 570.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company's stock worth $113,000 after buying an additional 59,452 shares during the period. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PMVP has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Oppenheimer raised PMV Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $6.00 target price for the company in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, PMV Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $5.80.

PMV Pharmaceuticals Trading Down 2.4 %

PMVP stock traded down $0.04 during midday trading on Tuesday, hitting $1.65. The stock had a trading volume of 90,413 shares, compared to its average volume of 392,795. The firm has a market cap of $85.39 million, a P/E ratio of -1.69 and a beta of 1.47. The business has a fifty day moving average price of $1.59 and a two-hundred day moving average price of $1.62. PMV Pharmaceuticals, Inc. has a 1-year low of $1.40 and a 1-year high of $3.47.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, equities analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.